MANKIND.NS Profit & Loss
Mankind Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:37
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹8,749.43 Cr. | ₹10,334.77 Cr. | ₹12,207.44 Cr. | ₹14,277.64 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹128.57 Cr. | ₹280.86 Cr. | ₹536.79 Cr. | ₹358.79 Cr. | OtherIncome |
| Total Income | ₹8,878.00 Cr. | ₹10,615.63 Cr. | ₹12,744.23 Cr. | ₹14,636.43 Cr. | Income |
| Cost of Materials Consumed | ₹1,813.66 Cr. | ₹1,853.52 Cr. | ₹2,016.35 Cr. | ₹2,288.03 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹809.24 Cr. | ₹1,409.85 Cr. | ₹1,655.69 Cr. | ₹1,727.97 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹290.74 Cr. | ₹-53.67 Cr. | ₹-183.00 Cr. | ₹36.12 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹1,918.47 Cr. | ₹2,274.73 Cr. | ₹2,692.37 Cr. | ₹3,183.90 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹44.47 Cr. | ₹33.53 Cr. | ₹429.41 Cr. | ₹639.28 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹325.92 Cr. | ₹398.25 Cr. | ₹621.22 Cr. | ₹886.18 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹2,016.68 Cr. | ₹2,315.28 Cr. | ₹3,008.10 Cr. | ₹3,424.21 Cr. | OtherExpenses |
| Total Expenses | ₹7,219.18 Cr. | ₹8,231.49 Cr. | ₹10,240.14 Cr. | ₹12,185.69 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹1,658.81 Cr. | ₹2,384.14 Cr. | ₹2,504.09 Cr. | ₹2,450.74 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹-129.75 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹1,658.81 Cr. | ₹2,384.14 Cr. | ₹2,504.09 Cr. | ₹2,320.99 Cr. | ProfitBeforeTax |
| Tax Expense | ₹361.56 Cr. | ₹457.59 Cr. | ₹509.74 Cr. | ₹394.58 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹1,309.68 Cr. | ₹1,941.77 Cr. | ₹2,011.12 Cr. | ₹1,938.10 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹1,281.86 Cr. | ₹1,912.90 Cr. | ₹1,986.43 Cr. | ₹1,912.93 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹32.00 | ₹47.75 | ₹49.28 | ₹46.35 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹32.00 | ₹47.68 | ₹49.19 | ₹46.28 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from MANKIND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).